Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism

European Journal of Endocrinology

Volumn 165, Issue 6, 2011, Pages 851-864

  Bollerslev, Jens ^a,b   Marcocci, Claudio ^c   Sosa, Manuel ^d   Nordenström, Jörgen ^e   Bouillon, Roger ^f   Mosekilde, Leif ^g  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALENDRONIC ACID; CALCIFEDIOL; CALCIMIMETIC AGENT; CALCIUM; CINACALCET; COLECALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE; PLACEBO; VITAMIN D;

AGE; BONE DISEASE; BONE MASS; BONE TURNOVER; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; EUROPE; FRAGILITY FRACTURE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; KIDNEY DYSFUNCTION; LONG TERM CARE; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATIENT CARE; PATIENT SELECTION; PREOPERATIVE CARE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; WATCHFUL WAITING;

ALENDRONATE; ANIMALS; BONE RESORPTION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; VITAMIN D;

EID: 81555203017     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0589     Document Type: Review

References (80)

1. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M & Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Journal of Clinical Endocrinology and Metabolism 2009 94 351-365. (doi:10.1210/jc.2008-1760)
2. NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Annals of Internal Medicine 1991 114 593-597.
3. Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R & Wells SA. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. Journal of Clinical Endocrinology and Metabolism 2002 87 5353-5361. (doi:10.1210/jc.2002-021370)
4. Bilezikian JP, Khan AA & Potts JT Jr. Guidelines for themanagement of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. Journal of Clinical Endocrinology and Metabolism 2009 94 335-339. (doi:10.1210/jc.2008-1763)
5. Cope O. The study of hyperparathyroidism at the Massachusetts General Hospital. New England Journal of Medicine 1966 274 1174-1182. (doi:10.1056/NEJM196605262742105)
6. Silverberg SJ & Bilezikian JP. The diagnosis and management of asymptomatic primary hyperparathyroidism. Nature Clinical Practice. Endocrinology & Metabolism 2006 2 494-503. (doi:10.1038/ncpendmet0265)
7. Fraser WD. Hyperparathyroidism. Lancet 2009 374 145-158. (doi:10.1016/S0140-6736(09)60507-9)
8. Ayturk S, Gursoy A, Bascil TN, Ertugrul DT & Guvener DN. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2006 91 4260-4263. (doi:10.1210/jc.2005-2825)
9. Elvius M, Lagrelius A, Nygren A, Alveryd A, Christensson TA & Nordenstrom J. Seventeen year follow-up study of bone mass in patients with mild asymptomatic hyperparathyroidism some of whom were operated on. European Journal of Surgery 1995 161 863-869. (Pubitemid 26019411)
10. Rao DS, Wilson RJ, Kleerekoper M & Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. Journal of Clinical Endocrinology and Metabolism 1988 67 1294-1298. (doi:10.1210/jcem-67-6- 1294)
11. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J & Silverberg SJ. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. Journal of Clinical Endocrinology and Metabolism 2008 93 3462-3470. (doi:10.1210/jc.2007-1215)
12. Silverberg SJ, Shane E, Jacobs TP, Siris E & Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. New England Journal of Medicine 1999 341 1249-1255. (doi:10.1056/NEJM199910213411701)
13. Silverberg SJ, Shane E, Dempster DW & Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. American Journal of Medicine 1999 107 561-567. (doi:10.1016/S0002-9343(99)00294-6)
14. Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. Journal of Bone and Mineral Research 2007 22 (Suppl 2) V100-V104. (doi:10.1359/jbmr.07s202)
15. Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O'Fallon WM & Melton LJ III. Survival after the diagnosis of hyperparathyroidism: a population-based study. American Journal of Medicine 1998 104 115-122. (doi:10.1016/S0002-9343(97)00270-2)
16. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS & Melton LJ III. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. Journal of Bone and Mineral Research 2006 21 171-177. (doi:10.1359/JBMR.050910)
17. Bilezikian JP, Meng X, Shi Y & Silverberg SJ. Primary hyperparathyroidism in women: a tale of two cities - New York and Beijing. International Journal of Fertility and Women's Medicine 2000 45 158-165. (Pubitemid 30619114)
18. Harinarayan CV, Gupta N & Kochupillai N. Vitamin D status in primary hyperparathyroidism in India. Clinical Endocrinology 1995 43 351-358. (doi:10.1111/j.1365-2265.1995.tb02043.x)
19. Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, Talpos GB & Parfitt AM. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. Journal of Clinical Endocrinology and Metabolism 2000 85 1054-1058. (doi:10.1210/jc.85.3.1054)
20. Rao DS, Agarwal G, Talpos GB, Phillips ER, Bandeira F, Mishra SK & Mithal A. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. Journal of Bone and Mineral Research 2002 17 (Suppl 2) N75-N80. (Pubitemid 35222316)
21. Lundgren E, Rastad J, Thrufjell E, Akerstrom G & Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997 121 287-294. (doi:10.1016/S0039-6060(97)90357-3)
22. Siilin H, Rastad J, Ljunggren O & Lundgren E. Disturbances of calcium homeostasis consistent with mild primary hyperparathyroidism in premenopausal women and associated morbidity. Journal of Clinical Endocrinology and Metabolism 2008 93 47-53. (doi:10.1210/jc.2007-0600)
23. Lundgren E, Szabo E, Ljunghall S, Bergstrom R, Holmberg L & Rastad J. Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism. BMJ 1998 317 848-851. (Pubitemid 28434552)
24. Siilin H, Lundgren E, Mallmin H, Mellström D, Ohlsson C, Karlsson M, Orwoll E & Ljunggren O. Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: Mr Os Sweden. World Journal of Surgery 2011 35 1266-1272. (doi:10.1007/s00268-011-1062-2)
25. Bolland MJ, Grey AB, Gamble GD & Reid IR. Association between primary hyperparathyroidism and increased body weight: a metaanalysis. Journal of Clinical Endocrinology and Metabolism 2005 90 1525-1530. (doi:10.1210/jc.2004- 1891)
26. Fitzpatrick LA, Bilezikian JP & Silverberg SJ. Parathyroid hormone and the cardiovascular system. Current Osteoporosis Reports 2008 6 77-83. (doi:10.1007/s11914-008-0014-8)
27. Hagstrom E, Lundgren E, Rastad J & Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. European Journal of Endocrinology 2006 155 33-39. (doi:10.1530/eje.1.02173)
28. Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaëlsson K & Arnlöv J. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009 119 2765-2771. (doi:10.1161/CIRCULATIONAHA.108. 808733)
29. Mollerup CL, Vestergaard P, Frokjaer VG, Mosekilde L, Christiansen P & Blichert-Toft M. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ 2002 325 807. (doi:10.1136/bmj.325.7368.807)
30. Vestergaard P & Mosekilde L. Fractures in patients with primary hyperparathyroidism: nationwide follow-up study of 1201 patients. World Journal of Surgery 2003 27 343-349. (doi:10.1007/s00268-002-6589-9)
31. Vestergaard P & Mosekilde L. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 2003 327 530-534. (doi:10.1136/bmj.327.7414.530)
32. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M & Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism.World Journal of Surgery 2003 27 216-222. (doi:10.1007/s00268-002-6589-9)
33. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, Oppo A, Miccoli P, Berti P, Bilezikian JP, Pinchera A & Marcocci C. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. Journal of Clinical Endocrinology and Metabolism 2007 92 3114-3121. (doi:10.1210/jc.2007-0219)
34. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, Varhaug JE, Baranowski M, Aanderud S, Franco C, Freyschuss B, Isaksen GA, Ueland T & Rosen T.Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. Journal of Clinical Endocrinology and Metabolism 2007 92 1687-1692. (doi:10.1210/jc.2006-1836)
35. Bollerslev J, Rosen T, Mollerup CL, Nordenström J, Baranowski M, Franco C, PernowY, Isaksen GA, Godang K, Ueland T & Jansson Son behalf of the SIPH Study Group. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2009 94 2255-2261. (doi:10.1210/jc.2008-2742)
36. Rao DS, Phillips ER, Divine GW & Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2004 89 5415-5422. (doi:10.1210/jc.2004-0028)
37. Walker MD & Silverberg SJ. Parathyroidectomy in asymptomatic primary hyperparathyroidism: improves "bones" but not "psychic moans". Journal of Clinical Endocrinology and Metabolism 2007 92 1613-1615. (doi:10.1210/jc.2007-0551)
38. Christiansen P, Steiniche T, Vesterby A, Mosekilde L, Hessov I & Melsen F. Primary hyperparathyroidism: iliac crest trabecular bone volume, structure, remodeling, and balance evaluated by histomorphometric methods. Bone 1992 13 41-49. (doi:10.1016/8756-3282(92)90360-9)
39. Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Heickendorff L & Mosekilde L. Primary hyperparathyroidism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three-year follow-up study. Bone 1999 25 589-595. (doi:10.1016/S8756-3282(99)00207-0)
40. Udelsman R, Pasieka JL, Sturgeon C, Young JE & Clark OH. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Journal of Clinical Endocrinology and Metabolism 2009 94 366-372. (doi:10.1210/jc.2008-1761)
41. Irvin GL III, Solorzano CC & Carneiro DM. Quick intraoperative parathyroid hormone assay: surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome. World Journal of Surgery 2004 28 1287-1292. (doi:10.1007/s00268-004-7708-6)
42. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Annals of Surgery 2002 235 665-670. (doi:10.1097/00000658- 200205000-00008)
43. Westerdahl J & Bergenfelz A. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: five-year follow-up of a randomized controlled trial. Annals of Surgery 2007 246 976-980. (doi:10.1097/SLA. 0b013e31815c3ffd)
44. Zanocco K, Angelos P & Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 2006 140 874-881. (doi:10.1016/j.surg.2006.07.032)
45. Zanocco K, Heller M & Sturgeon C. Cost-effectiveness of parathyroidectomy for primary hyperparathyroidism. Endocrine Practice 2011 17 (Suppl 1) 69-74. (doi:10.4158/EP10311.RA)
46. Persson A, Bollerslev J, Rosen T, Mollerup CL, Franco C, Isaksen GA, Ueland T, Jansson S & Caidahl K & SIPH Study Group. Effect of surgery on cardiac structure and function in mild primary hyperparathyroidism. Clinical Endocrinology 2011 74 174-180. (doi:10.1111/j.1365-2265.2010.03909.x)
47. Rolighed L, Bollerslev J & Mosekilde L. Vitamin D treatment in primary hyperparathyroidism. Current Drug Safety 2011 6 100-107.
48. Hagenau T, Vest R, Gissel TN, Poulsen CS, Erlandsen M, Mosekilde L & Vestergaard P. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporosis International 2009 20 133-140. (doi:10.1007/s00198-008-0626-y)
49. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocrine Reviews 2001 22 477-501. (doi:10.1210/er.22.4.477)
50. Stein EM, Dempster DW, Udesky J, Zhou H, Bilezikian JP, Shane E & Silverberg SJ. Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone 2011 48 557-561. (doi:10.1016/j.bone. 2010.10.004)
51. Boudou P, Ibrahim F, Cormier C, Sarfati E & Souberbielle JC. Potential utility of high preoperative levels of serum type I collagen markers in postmenopausal women with primary hyperparathyroidism with respect to their short-term variations after parathyroidectomy. Journal of Bone and Mineral Metabolism 2009 27 240-246. (doi:10.1007/s00774-008-0033-7)
52. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P & Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clinical Endocrinology 2005 63 506-513. (doi:10.1111/j.1365-2265.2005.02371.x)
53. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P & Mosekilde L. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. European Journal of Endocrinology 2006 155 237-244. (doi:10.1530/eje.1.02197)
54. Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P & Mosekilde L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clinical Endocrinology 2008 68 707-715. (doi:10.1111/j.1365-2265.2007.03109.x)
55. Walker MD, Fleischer JB, Di Tullio MR, Homma S, Rundek T, Stein EM, Zhang C, Taggart T, McMahon DJ & Silverberg SJ. Cardiac structure and diastolic function in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2010 95 2172-2179. (doi:10.1210/jc.2009-2072)
56. Zierold C, Mings JA & DeLuca HF. Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D3 and parathyroid hormone. Journal of Cellular Biochemistry 2003 88 234-237. (doi:10.1002/jcb.10341)
57. Farahnak P, Larfars G, Sten-Linder M & Nilsson IL. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. Journal of Clinical Endocrinology and Metabolism 2011 96 2112-2118. (doi:10.1210/jc.2011-0238)
58. Amstrup AK, Rejnmark L, Vestergaard P, Sikjaer T, Rolighed L, Heickendorff L & Mosekilde L. Vitamin D status, physical performance and body mass in patients surgically cured for primary hyperparathyroidism compared with healthy controls - a cross-sectional study. Clinical Endocrinology 2011 74 130-136. (doi:10.1111/j.1365-2265.2010.03906.x)
59. Arnold A, Shattuck TM, Mallya SM, Krebs LJ, Costa J, Gallagher J, Wild Y & Saucier K. Molecular pathogenesis of primary hyperparathyroidism. Journal of Bone and Mineral Research 2002 17 (Suppl 2) N30-N36. (Pubitemid 35222310)
60. Sultan AH, Bruckner FE & Eastwood JB. Association between prolonged dietary vitamin D deficiency and autonomous hyperparathyroidism. BMJ 1989 299 236-237. (doi:10.1136/bmj.299.6693.236)
61. Heath DA, Van't HW, Barnes AD & Gray JG. Value of 1-alphahydroxy vitamin D3 in treatment of primary hyperparathyroidism before parathyroidectomy. BMJ 1979 1 450-452. (doi:10.1136/bmj.1.6161.450)
62. Lind L, Wengle B, Sorensen OH, Wide L, Akerstrom G & Ljunghall S. Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism. Acta Endocrinologica 1989 120 250-256. (Pubitemid 19049767)
63. Kantorovich V, Gacad MA, Seeger LL & Adams JS. Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2000 85 3541-3543. (doi:10.1210/jc.85.10.3541)
64. LoCascio V, Adami S, Galvanini G, Ferrari M, Cominacini L & Tartarotti D. Substrate-product relation of 1-hydroxylase activity in primary hyperparathyroidism. New England Journal of Medicine 1985 313 1123-1125. (doi:10.1056/NEJM198510313131804)
65. Grey A, Lucas J, Horne A, Gamble G, Davidson JS & Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. Journal of Clinical Endocrinology and Metabolism 2005 90 2122-2126. (doi:10.1210/jc.2004-1772)
66. Grubbs EG, Rafeeq S, Jimenez C, Feng L, Lee JE, Evans DB & Perrier ND. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 2008 144 852-858. (doi:10.1016/j.surg.2008.06.032)
67. Tucci JR. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. European Journal of Endocrinology 2009 161 189-193. (doi:10.1530/EJE-08-0901)
68. Isidro ML & Ruano B. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 2009 36 305-310. (doi:10.1007/s12020-009-9211-1)
69. Stewart ZA, Blackford A, Somervell H, Friedman K, Garrett-Mayer E, Dackiw AP & Zeiger MA. 25-Hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery 2005 138 1018-1025. (doi:10.1016/j.surg.2005.09.018)
70. Untch BR, Barfield ME, Dar M, Dixit D, Leight GS Jr & Olson JA Jr. Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 2007 142 1022-1026. (doi:10.1016/j.surg.2007.09.026)
71. Grey AB, Stapleton JP, Evans MC, Tatnell MA & Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Annals of Internal Medicine 1996 125 360-368. (Pubitemid 126449705)
72. Rossini M, Gatti D, Isaia G, Sartori L, Braga V & Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. Journal of Bone and Mineral Research 2001 16 113-119. (doi:10.1359/jbmr.2001.16.1.113)
73. Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, Lo KW & Cockram CS. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2003 88 581-587. (doi:10.1210/jc.2002-020890)
74. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z & Syed ZA. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2004 89 3319-3325. (doi:10.1210/jc.2003-030908)
75. Sankaran S, Gamble G, Bolland M, Reid IR & Grey A. Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2010 95 1653-1662. (doi:10.1210/jc. 2009-2384)
76. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D & Martin D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. Journal of Pharmacology and Experimental Therapeutics 2004 308 627-635. (doi:10.1124/jpet.103.057273)
77. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD & Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2003 88 5644-5649. (doi:10.1210/jc.2002-021597)
78. Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S & Shoback D. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. Journal of Clinical Endocrinology and Metabolism 2009 94 4860-4867. (doi:10.1210/jc.2009- 1472)
79. Falchetti A, Cilotti A, Vaggelli L, Masi L, Amedei A, Cioppi F, Tonelli F & Brandi ML. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nature Clinical Practice. Endocrinology & Metabolism 2008 4 351-357. (Pubitemid 351733458)
80. Moyes VJ, Monson JP, Chew SL & Akker SA. Clinical use of cinacalcet in MEN1 hyperparathyroidism. International Journal of Endocrinology 2010 2010 906163. (doi:10.1155/2010/906163)